Synartro
Phase 1/2Synartro is a clinical stage Swedish life science company developing local injection treatments to provide superior and sustained efficacy without systemic side-effects. This is achieved by chemically binding existing proven drugs to the base compound in our novel local injection technology.
Founded
2021
Focus
Drug Delivery
About
Synartro is a clinical stage Swedish life science company developing local injection treatments to provide superior and sustained efficacy without systemic side-effects. This is achieved by chemically binding existing proven drugs to the base compound in our novel local injection technology.
Funding History
1Total raised: $1.2M
Seed$1.2MChalmers VenturesJun 15, 2021
Company Info
TypePrivate
Founded2021
LocationStockholm, Sweden
StagePhase 1/2
Contact
SIMILAR COMPANIES
Basic Genomics
Pre-clinical · Stockholm
2A Pharma
Phase 1 · Stockholm
Abliva
Pre-clinical · Lund
Affibody
Phase 1 · Solna
Alligator Bioscience
Phase 1 · Lund
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile